Loading…
Loading…
PARSIPPANY, NJ, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (OTCID: IDXG) (“Interpace” or the “Company”), an emerging leader in enabling personalized medicine, today announced that it will effect a 1-for-5 reverse stock split (“Reverse Stock Split”) of its issued and outstanding common stock. The Reverse Stock Split will become effective at 12:01 a.m. Eastern Time on August 27, 2026, and Interpace common stock is expected to begin trading on a split-adjusted basis on the OTCID quotation system (“OTCID”) as of the commencement of market open that same day. Interpace's ticker symbol on the OTCID will temporarily change to IDXGD for a period of 20 trading days, including the effective date. The new CUSIP number for the common stock following the Reverse Stock Split will be 46062X402.
Profitability This table compares Ethema Health and Interpace Biosciences' net margins, return on equity and return on assets. Net Margins Return on Equity Return on Assets Ethema Health -11.61% N/A -7.48% Interpace Biosciences 65.25% 219.07% 105.05% Insider and Institutional Ownership 5.7% of Interpace Biosciences shares are held by institutional investors. 55.7% of Ethema Health shares
Q2 Revenue of $9. 1 millionQ2 Income from Continuing Operations of $0. 3 millionQ2 Thyroid volume year-over-year increase of 6%Q2 Thyroid revenue year-over-year increase of 9%Trailing twelve-month thyroid revenue of $36. 1 million, an increase of 11% on a comparable thyroid-only basis PARSIPPANY, NJ, Aug.
Q1 Revenue of $9. 0 million Q1 Income from Continuing Operations of $0. 8 million Q1 Thyroid volume year-over-year increase of 10% Q1 Thyroid revenue year-over-year increase of 12% PARSIPPANY, NJ, May 12, 2026 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. ("Interpace" or the "Company") (OTCQX: IDXG) today announced financial results for the first quarter ended March 31, 2026 and provided a business and financial update.
PARSIPPANY, NJ, May 12, 2026 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. ("Interpace" or the "Company") (OTCQX: IDXG) today announced financial results for the first quarter ended March 31, 2026 and provided a business and financial update.
Institutional and Insider Ownership 7.6% of Retractable Technologies shares are owned by institutional investors. Comparatively, 5.7% of Interpace Biosciences shares are owned by institutional investors. 59.5% of Retractable Technologies shares are owned by insiders. Comparatively, 5.5% of Interpace Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money
Earnings and Valuation This table compares Dynatronics and Interpace Biosciences"s top-line revenue, earnings per share and valuation. Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Dynatronics $33.60 million 0.00 -$2.70 million ($1.35) -0.01 Interpace Biosciences $38.73 million 0.23 $24.58 million ($0.02) -99.88 Interpace Biosciences has higher revenue and earnings than Dynatronics. Interpace
Interpace Biosciences, Inc. (OTCMKTS:IDXG - Get Free Report) crossed above its two hundred day moving average during trading on Monday. The stock has a two hundred day moving average of $1.41 and traded as high as $2.10. Interpace Biosciences shares last traded at $2.0460, with a volume of 4,515 shares trading hands. Interpace Biosciences